Gaining ground in progressive multifocal leukoencephalopathy
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
The development of highly active antiretroviral ther apy (HAART) has had a dramatic impact on the prognosis of HIV infection1,2 and on its associated opportunistic processes.3,4 This is illustrated in the report by Clifford et al. in the current issue of Neurology,5 which describes improved survival (median, 46.4 weeks) in a group of 25 HIV-infected patients with progressive multifocal leukoencephalopathy (PML) on HAART compared with the survival of historic controls (median, 10.6 weeks). Although Clifford et al.’s series has the inherent limitations of any observational study, the magnitude of the differences is large, and is consistent with other published reports and the anecdotal impressions of clinicians who care for patients with PML in the era of HAART. The …
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Fabricio Ferreira de Oliveira and Dr. Alan Cronemberger Andrade
► Watch
Related Articles
Alert Me
Recommended articles
-
Articles
PML-IRIS in patients with HIV infectionClinical manifestations and treatment with steroidsK. Tan, R. Roda, L. Ostrow et al.Neurology, January 07, 2009 -
Brief Communications
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyD.B. Clifford, C. Yiannoutsos, M. Glicksman et al.Neurology, February 01, 1999 -
Articles
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathyP. Vermersch, L. Kappos, R. Gold et al.Neurology, May 16, 2011 -
Views & Reviews
Reactivation of JC virus and development of PML in patients with multiple sclerosisK. Khalili, M. K. White, F. Lublin et al.Neurology, March 26, 2007